Compare ADAG & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADAG | TKNO |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.3M | 138.1M |
| IPO Year | 2020 | 2021 |
| Metric | ADAG | TKNO |
|---|---|---|
| Price | $3.81 | $3.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 222.3K | 140.8K |
| Earning Date | 03-24-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $40,520,000.00 |
| Revenue This Year | $3,688.61 | $8.27 |
| Revenue Next Year | $17.39 | $13.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.35 |
| 52 Week Low | $1.33 | $1.91 |
| 52 Week High | $4.58 | $7.48 |
| Indicator | ADAG | TKNO |
|---|---|---|
| Relative Strength Index (RSI) | 56.77 | 63.28 |
| Support Level | $1.69 | $3.01 |
| Resistance Level | $4.58 | $5.39 |
| Average True Range (ATR) | 0.46 | 0.23 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 48.95 | 88.62 |
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.